Effect of VDCC blockers on spontaneous release at neonatal rat neuromuscular junction
VDCC Blocker | Concentration | Control | Treated | Treated/Control | Significance |
|---|---|---|---|---|---|
| Control | 2.61 ± 0.19 (350/29)a | — | 1 | ||
| Nifedipine | 10 μM | 3.90 ± 0.66 (90/6) | 193.10 ± 15.2 (101/6) | 49.5 | p < 0.001 |
| Bay-K | 10 μM | 2.28 ± 0.80 (51/5) | 30.50 ± 6.20 (41/3) | 13.4 | p < 0.001 |
| Isradipine | 1 μM | 3.64 ± 0.94 (34/3) | 2.90 ± 0.47 (38/3) | 0.8 | NS |
| Nitrendipine | 10 μM | 2.87 ± 0.52 (40/3) | 4.07 ± 0.99 (40/3) | 1.42 | NS |
| Calciseptine | 300 nM | 2.98 ± 0.49 (39/3) | 2.50 ± 0.60 (34/3) | 0.84 | NS |
| ω-Aga IVA | 100 nM | 2.53 ± 0.36 (22/3) | 3.10 ± 0.58 (35/3) | 1.22 | NS |
| ω-Cgtx GVIA | 5 μM | 2.37 ± 0.36 (43/4) | 2.49 ± 0.60 (59/4) | 1.05 | NS |
↵ a Numbers in parentheses represent number of fibers/number of muscles.